BNP Paribas Exane analyst Peter Verdult initiated coverage of GSK (GSK) with a Neutral rating and $35.25 price target Stay Ahead of the Market: ...

GSK plc ( NYSE: GSK) has failed to meet key ethical and regulatory standards in how it marketed and provided prescribing information for its drug Omjjara, according to a ruling issued Tuesday by an ...

As we’ve been reporting, US Vice-President JD Vance says there is a “good chance” that the US and UK will come to a mutually ...

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk ...

Goldman Sachs says the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices published its final agenda ...

CEO Emma Walmsley said the company has been anticipating tariffs on the industry and is “confident” the company can navigate through it, Ashleigh Furlong and Ruth David of Bloomberg reports. The U.S.